Clinical Trial

Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above

Name: Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above — clinical trial record (NCT07327398)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To evaluate the immunogenicity of administering one dose of influenza virus split vaccine (0.7mL/dose) to individuals aged 60 and above.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-12-25.

Trial Details

NCT Number	NCT07327398
Lead Sponsor	Shanghai Institute Of Biological Products
Conditions	Influenza
Enrollment	1,200 participants
Start Date	2026-01-07
Primary Completion	2026-09-30 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-15